Clinical Trial Update: A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating YTS109 cell therapy for relapsed/refractory autoimmune diseases is currently recruiting. The study covers multiple indicatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Antiphospholipid Syndrome
• Igg4-related Disease
• Inflammatory Myopathy
• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• YTS109 cell (YTS109)

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Status: RECRUITING